NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

市場調查報告書

細胞療法的全球市場

Cell Therapy

出版商 Global Industry Analysts, Inc. 商品編碼 997423
出版日期 內容資訊 英文 171 Pages
商品交期: 最快1-2個工作天內
價格
細胞療法的全球市場 Cell Therapy
出版日期: 2021年04月01日內容資訊: 英文 171 Pages
簡介

全球細胞療法的市場規模,預計在分析期間(2020年∼2027年)將以5.1%的年複合成長率增長,從2020年的56億美元,到2027年達到79億美元。

本報告所分析的市場區隔之一的自體移植部門,在分析期間中預計將以5.9%的年複合成長率增長,達到35億美元。

本報告提供全球細胞療法市場的相關調查,提供市場佔有率,Covid-19的影響,趨勢和成長要素,各地區的市場分析,競爭情形,主要企業的簡介等資訊。

調查對象企業範例

  • Anterogen Co., Ltd.
  • Celgene Corporation
  • Cells for Cells S.A. (C4C)
  • Fibrocell Science, Inc.
  • GlaxoSmithKline PLC
  • JCR Pharmaceuticals Co., Ltd.
  • Kolon TissueGene, Inc.
  • Medipost Co., Ltd.
  • Novartis AG
  • NuVasive, Inc.
  • Osiris Therapeutics, Inc.
  • Pharmicell Co., Ltd.
  • Stemedica Cell Technologies, Inc.
  • Vericel Corporation

目錄

I. 調查手法

II. 摘要整理

  • 市場概要
    • 影響者市場洞察
    • 全球市場的軌跡
    • Covid-19的影響與即將到來的全球景氣衰退
  • 主要企業
  • 趨勢與推動要素
  • 全球市場預測

III. 市場分析

  • 美國
  • 加拿大
  • 日本
  • 中國
  • 歐洲
  • 法國
  • 德國
  • 義大利
  • 英國
  • 其他歐洲
  • 亞太地區
  • 其他地區

IV. 競爭

  • 企業簡介:42公司

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: MCP10952

Abstract:

Global Cell Therapy Market to Reach $7.9 Billion by 2027

Amid the COVID-19 crisis, the global market for Cell Therapy estimated at US$5.6 Billion in the year 2020, is projected to reach a revised size of US$7.9 Billion by 2027, growing at aCAGR of 5.1% over the period 2020-2027. Autologous, one of the segments analyzed in the report, is projected to record 5.9% CAGR and reach US$3.5 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Allogenic segment is readjusted to a revised 4.4% CAGR for the next 7-year period.

The U.S. Market is Estimated at $1.7 Billion, While China is Forecast to Grow at 4.8% CAGR

The Cell Therapy market in the U.S. is estimated at US$1.7 Billion in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$1.4 Billion by the year 2027 trailing a CAGR of 4.8% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 4.7% and 4.2% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 4.7% CAGR.

Select Competitors (Total 42 Featured) -

  • Anterogen Co., Ltd.
  • Celgene Corporation
  • Cells for Cells S.A. (C4C)
  • Fibrocell Science, Inc.
  • GlaxoSmithKline PLC
  • JCR Pharmaceuticals Co., Ltd.
  • Kolon TissueGene, Inc.
  • Medipost Co., Ltd.
  • Novartis AG
  • NuVasive, Inc.
  • Osiris Therapeutics, Inc.
  • Pharmicell Co., Ltd.
  • Stemedica Cell Technologies, Inc.
  • Vericel Corporation

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Impact of Covid-19 and a Looming Global Recession
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Current & Future Analysis for Cell Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 2: World Historic Review for Cell Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 3: World 15-Year Perspective for Cell Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2012, 2020 & 2027
    • TABLE 4: World Current & Future Analysis for Autologous by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 5: World Historic Review for Autologous by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 6: World 15-Year Perspective for Autologous by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
    • TABLE 7: World Current & Future Analysis for Allogenic by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 8: World Historic Review for Allogenic by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 9: World 15-Year Perspective for Allogenic by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
    • TABLE 10: World Current & Future Analysis for Clinical-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 11: World Historic Review for Clinical-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 12: World 15-Year Perspective for Clinical-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
    • TABLE 13: World Current & Future Analysis for Research-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 14: World Historic Review for Research-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 15: World 15-Year Perspective for Research-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027

III. MARKET ANALYSIS

  • UNITED STATES
    • TABLE 16: USA Current & Future Analysis for Cell Therapy by Therapy - Autologous and Allogenic - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 17: USA Historic Review for Cell Therapy by Therapy - Autologous and Allogenic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 18: USA 15-Year Perspective for Cell Therapy by Therapy - Percentage Breakdown of Value Sales for Autologous and Allogenic for the Years 2012, 2020 & 2027
    • TABLE 19: USA Current & Future Analysis for Cell Therapy by Application - Clinical-Use and Research-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 20: USA Historic Review for Cell Therapy by Application - Clinical-Use and Research-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 21: USA 15-Year Perspective for Cell Therapy by Application - Percentage Breakdown of Value Sales for Clinical-Use and Research-Use for the Years 2012, 2020 & 2027
  • CANADA
    • TABLE 22: Canada Current & Future Analysis for Cell Therapy by Therapy - Autologous and Allogenic - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 23: Canada Historic Review for Cell Therapy by Therapy - Autologous and Allogenic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 24: Canada 15-Year Perspective for Cell Therapy by Therapy - Percentage Breakdown of Value Sales for Autologous and Allogenic for the Years 2012, 2020 & 2027
    • TABLE 25: Canada Current & Future Analysis for Cell Therapy by Application - Clinical-Use and Research-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 26: Canada Historic Review for Cell Therapy by Application - Clinical-Use and Research-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 27: Canada 15-Year Perspective for Cell Therapy by Application - Percentage Breakdown of Value Sales for Clinical-Use and Research-Use for the Years 2012, 2020 & 2027
  • JAPAN
    • TABLE 28: Japan Current & Future Analysis for Cell Therapy by Therapy - Autologous and Allogenic - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 29: Japan Historic Review for Cell Therapy by Therapy - Autologous and Allogenic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 30: Japan 15-Year Perspective for Cell Therapy by Therapy - Percentage Breakdown of Value Sales for Autologous and Allogenic for the Years 2012, 2020 & 2027
    • TABLE 31: Japan Current & Future Analysis for Cell Therapy by Application - Clinical-Use and Research-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 32: Japan Historic Review for Cell Therapy by Application - Clinical-Use and Research-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 33: Japan 15-Year Perspective for Cell Therapy by Application - Percentage Breakdown of Value Sales for Clinical-Use and Research-Use for the Years 2012, 2020 & 2027
  • CHINA
    • TABLE 34: China Current & Future Analysis for Cell Therapy by Therapy - Autologous and Allogenic - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 35: China Historic Review for Cell Therapy by Therapy - Autologous and Allogenic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 36: China 15-Year Perspective for Cell Therapy by Therapy - Percentage Breakdown of Value Sales for Autologous and Allogenic for the Years 2012, 2020 & 2027
    • TABLE 37: China Current & Future Analysis for Cell Therapy by Application - Clinical-Use and Research-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 38: China Historic Review for Cell Therapy by Application - Clinical-Use and Research-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 39: China 15-Year Perspective for Cell Therapy by Application - Percentage Breakdown of Value Sales for Clinical-Use and Research-Use for the Years 2012, 2020 & 2027
  • EUROPE
    • TABLE 40: Europe Current & Future Analysis for Cell Therapy by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 41: Europe Historic Review for Cell Therapy by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 42: Europe 15-Year Perspective for Cell Therapy by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2012, 2020 & 2027
    • TABLE 43: Europe Current & Future Analysis for Cell Therapy by Therapy - Autologous and Allogenic - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 44: Europe Historic Review for Cell Therapy by Therapy - Autologous and Allogenic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 45: Europe 15-Year Perspective for Cell Therapy by Therapy - Percentage Breakdown of Value Sales for Autologous and Allogenic for the Years 2012, 2020 & 2027
    • TABLE 46: Europe Current & Future Analysis for Cell Therapy by Application - Clinical-Use and Research-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 47: Europe Historic Review for Cell Therapy by Application - Clinical-Use and Research-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 48: Europe 15-Year Perspective for Cell Therapy by Application - Percentage Breakdown of Value Sales for Clinical-Use and Research-Use for the Years 2012, 2020 & 2027
  • FRANCE
    • TABLE 49: France Current & Future Analysis for Cell Therapy by Therapy - Autologous and Allogenic - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 50: France Historic Review for Cell Therapy by Therapy - Autologous and Allogenic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 51: France 15-Year Perspective for Cell Therapy by Therapy - Percentage Breakdown of Value Sales for Autologous and Allogenic for the Years 2012, 2020 & 2027
    • TABLE 52: France Current & Future Analysis for Cell Therapy by Application - Clinical-Use and Research-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 53: France Historic Review for Cell Therapy by Application - Clinical-Use and Research-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 54: France 15-Year Perspective for Cell Therapy by Application - Percentage Breakdown of Value Sales for Clinical-Use and Research-Use for the Years 2012, 2020 & 2027
  • GERMANY
    • TABLE 55: Germany Current & Future Analysis for Cell Therapy by Therapy - Autologous and Allogenic - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 56: Germany Historic Review for Cell Therapy by Therapy - Autologous and Allogenic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 57: Germany 15-Year Perspective for Cell Therapy by Therapy - Percentage Breakdown of Value Sales for Autologous and Allogenic for the Years 2012, 2020 & 2027
    • TABLE 58: Germany Current & Future Analysis for Cell Therapy by Application - Clinical-Use and Research-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 59: Germany Historic Review for Cell Therapy by Application - Clinical-Use and Research-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 60: Germany 15-Year Perspective for Cell Therapy by Application - Percentage Breakdown of Value Sales for Clinical-Use and Research-Use for the Years 2012, 2020 & 2027
  • ITALY
    • TABLE 61: Italy Current & Future Analysis for Cell Therapy by Therapy - Autologous and Allogenic - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 62: Italy Historic Review for Cell Therapy by Therapy - Autologous and Allogenic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 63: Italy 15-Year Perspective for Cell Therapy by Therapy - Percentage Breakdown of Value Sales for Autologous and Allogenic for the Years 2012, 2020 & 2027
    • TABLE 64: Italy Current & Future Analysis for Cell Therapy by Application - Clinical-Use and Research-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 65: Italy Historic Review for Cell Therapy by Application - Clinical-Use and Research-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 66: Italy 15-Year Perspective for Cell Therapy by Application - Percentage Breakdown of Value Sales for Clinical-Use and Research-Use for the Years 2012, 2020 & 2027
  • UNITED KINGDOM
    • TABLE 67: UK Current & Future Analysis for Cell Therapy by Therapy - Autologous and Allogenic - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 68: UK Historic Review for Cell Therapy by Therapy - Autologous and Allogenic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 69: UK 15-Year Perspective for Cell Therapy by Therapy - Percentage Breakdown of Value Sales for Autologous and Allogenic for the Years 2012, 2020 & 2027
    • TABLE 70: UK Current & Future Analysis for Cell Therapy by Application - Clinical-Use and Research-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 71: UK Historic Review for Cell Therapy by Application - Clinical-Use and Research-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 72: UK 15-Year Perspective for Cell Therapy by Application - Percentage Breakdown of Value Sales for Clinical-Use and Research-Use for the Years 2012, 2020 & 2027
  • REST OF EUROPE
    • TABLE 73: Rest of Europe Current & Future Analysis for Cell Therapy by Therapy - Autologous and Allogenic - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 74: Rest of Europe Historic Review for Cell Therapy by Therapy - Autologous and Allogenic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 75: Rest of Europe 15-Year Perspective for Cell Therapy by Therapy - Percentage Breakdown of Value Sales for Autologous and Allogenic for the Years 2012, 2020 & 2027
    • TABLE 76: Rest of Europe Current & Future Analysis for Cell Therapy by Application - Clinical-Use and Research-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 77: Rest of Europe Historic Review for Cell Therapy by Application - Clinical-Use and Research-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 78: Rest of Europe 15-Year Perspective for Cell Therapy by Application - Percentage Breakdown of Value Sales for Clinical-Use and Research-Use for the Years 2012, 2020 & 2027
  • ASIA-PACIFIC
    • TABLE 79: Asia-Pacific Current & Future Analysis for Cell Therapy by Therapy - Autologous and Allogenic - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 80: Asia-Pacific Historic Review for Cell Therapy by Therapy - Autologous and Allogenic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 81: Asia-Pacific 15-Year Perspective for Cell Therapy by Therapy - Percentage Breakdown of Value Sales for Autologous and Allogenic for the Years 2012, 2020 & 2027
    • TABLE 82: Asia-Pacific Current & Future Analysis for Cell Therapy by Application - Clinical-Use and Research-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 83: Asia-Pacific Historic Review for Cell Therapy by Application - Clinical-Use and Research-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 84: Asia-Pacific 15-Year Perspective for Cell Therapy by Application - Percentage Breakdown of Value Sales for Clinical-Use and Research-Use for the Years 2012, 2020 & 2027
  • REST OF WORLD
    • TABLE 85: Rest of World Current & Future Analysis for Cell Therapy by Therapy - Autologous and Allogenic - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 86: Rest of World Historic Review for Cell Therapy by Therapy - Autologous and Allogenic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 87: Rest of World 15-Year Perspective for Cell Therapy by Therapy - Percentage Breakdown of Value Sales for Autologous and Allogenic for the Years 2012, 2020 & 2027
    • TABLE 88: Rest of World Current & Future Analysis for Cell Therapy by Application - Clinical-Use and Research-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 89: Rest of World Historic Review for Cell Therapy by Application - Clinical-Use and Research-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 90: Rest of World 15-Year Perspective for Cell Therapy by Application - Percentage Breakdown of Value Sales for Clinical-Use and Research-Use for the Years 2012, 2020 & 2027

IV. COMPETITION

  • Total Companies Profiled: 42